News

Bapineuzumab fails phase III
Enlarge image

BusinessIreland

Bapineuzumab fails phase III

26.07.2012 - Pfizer and Johnson & Johnson report that Bapineuzumab failed the first of four phase III trials.

The monoclonal antibody Bapineuzumab could not outperform a placebo in moderating symptoms of mild-to-moderate Alzheimer's disease. Expectations on an intravenous formulation of the drug to help a group of patients sharing the so called ApoE4 (apolipoprotein E epsilon 4) genotype could not be fulfilled. Pfizer did not release details of the study’s outcome, but a principal investigator in the trial, Reisa Sperling, told The New York Times that "there was absolutely no evidence at all of a clinical benefit of treatment on either of the primary measures." The antibody developed by the Irish company Elan and US company Pfizer is tested in a large-scale Alzheimer's Immunotherapy Program for its suitability for treating the most common form of dementia. Meanwhile Johnson & Johnson joined the team for a total of four clinical trials. 1100 patients participated in the trail, all of them carriers of the ApoE4 risk gene. It is possible that patients without this gene modification could gain more profit from the agent. A second study with this group will start in the following weeks, two others are still ongoing.

Bapineuzumab is the follow up agent of AN1792, a vaccine which also failed. AN1792 successfully stimulated the formation of antibodies against beta amyloid – a protein that can exert toxic effects in the brain and is believed to play a central role in the pathology of Alzheimer's disease – in animal studies. But in 2002, a phase II trial had to be stopped because of safety issues. Aseptic meningoencephalitis and leukoencephalopathy were diagnosed in 6 percent of the participants. Nevertheless, some hints were given that the vaccine achieved an effect. The same effects were expected for Bapineuzumab, of course without the negative consequences.

http://www.european-biotechnology-news.com/news/news/2012-03/bapineuzumab-fails-phase-iii.html

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

Events

All Events

Current issue

All issues

Product of the week

Products